For example, in prostate cancer, prostaglandin E2 (PGE2) activates NR4A-RXR heterodimer to enhance micrometastasis; this effect can be reversed by cyclooxygenase 2 (COX2) inhibitor in cancer suppression (28). Here, PTGS2 is linked to prostate carcinoma.